The Technical AnalystExchange: TSX Industry: Diagnostics & Research
Spectral Medical Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
-3.37% $0.430
America/New_York / 3 mai 2024 @ 15:59
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 119.79 mill |
| EPS: | -0.0600 |
| P/E: | -7.17 |
| Earnings Date: | May 10, 2024 |
| SharesOutstanding: | 278.58 mill |
| Avg Daily Volume: | 0.0847 mill |
| RATING 2024-05-03 |
|---|
| C |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Buy | |
| Return On Asset: | Strong Sell | |
| DE: | Strong Sell | |
| P/E: | Sell | |
| Price To Book: | Strong Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -7.17 | sector: PE 21.44 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -7.17 | industry: PE -4.45 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-0.0583 (-113.56%) $-0.488 |
| Date: 2024-05-03 |
| Expected Trading Range (DAY) |
|---|
|
$ 0.408 - 0.462 ( +/- 6.21%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 |
| Volume Signals | |
|---|---|
| Price | $0.430 (-3.37% ) |
| Volume | 0.0053 mill |
| Avg. Vol. | 0.0847 mill |
| % of Avg. Vol | 6.28 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For EDT.TO
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
EDT.TO
Spectral Medical Inc., together with its subsidiaries, focuses on the development and commercialization of products for the treatment of septic shock and renal disease in North America. The company markets Endotoxin Activity Assay, a rapid in vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops and manufactures monoclonal and polyclonal antibodies, recombinant cardiac proteins, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies; and develops platform for renal replacement therapy. The company was formerly known as Spectral Diagnostics Inc. and changed its name to Spectral Medical Inc. in December 2014. Spectral Medical Inc. was incorporated in 1991 and is headquartered in Toronto, Canada.